Axsome Malta v. Aurobindo Pharma: Sunosi® Patent Case Consolidated in D.N.J.
Axsome Malta filed suit against Aurobindo Pharma in the District of New Jersey asserting Orange Book-listed patents covering Sunosi® (solriamfetol) oral tablets. The action — one of four related cases — was terminated after just 40 days when Axsome and both defendants jointly moved to consolidate all proceedings into a single litigation track.
Four Sunosi® ANDA suits merged into a single consolidated track
On May 1, 2025, Axsome Malta, Ltd. and co-plaintiff Axsome Therapeutics, Inc. filed Civil Action No. 2:25-cv-03721 in the District of New Jersey against Aurobindo Pharma, Ltd., asserting infringement of US12194016B2 — an Orange Book-listed patent for Axsome’s Sunosi® (solriamfetol) oral tablets, a wakefulness-promoting agent approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.
The May 2025 complaint was the fourth in a series of related ANDA-triggered actions filed by Axsome in the same district: two actions filed November 20, 2024 (against Alkem Laboratories and Aurobindo respectively), one filed January 21, 2025 (against Aurobindo), and the instant action. On June 10, 2025 — just 40 days after filing — Axsome and both defendants jointly requested consolidation of all four cases, resulting in termination of this docket.
The rapid closure of this docket is consistent with standard ANDA litigation practice, where parallel cases asserting the same Orange Book patents against related generic challengers are routinely merged for efficiency. The public record does not reveal the terms of any substantive agreement between the parties; the consolidation suggests coordinated case management rather than settlement. The merged proceedings will determine whether Aurobindo and Alkem may launch generic solriamfetol before Axsome’s listed patents expire.
Filing to Case Consolidated in 40 days
40-day lifespan before consolidation — significantly shorter than the median ANDA patent case
Case consolidated: what the merger means for both parties
Consolidation terminates this docket — litigation continues
Case consolidation under Fed. R. Civ. P. 42(a) merges actions sharing common questions of law or fact into a single proceeding. Termination of docket No. 2:25-cv-03721 does not end the underlying dispute; the Orange Book patent infringement claims survive and will be adjudicated in the consolidated action. No merits ruling has been made on validity or infringement.
No merits ruling issuedAxsome retains full enforcement rights in consolidated case
Consolidation does not diminish Axsome’s patent position. All infringement claims under US12194016B2 and any other Orange Book-listed Sunosi® patents carry forward into the merged docket. Axsome benefits from streamlined discovery and a single trial track, potentially reducing litigation costs while maintaining 30-month statutory stay protections triggered by the original ANDA filings.
Claims preserved in consolidationAurobindo and Alkem face unified litigation front
Consolidation means Aurobindo and co-defendant Alkem Laboratories will litigate validity and non-infringement of Axsome’s Sunosi® patents in a single proceeding. While consolidation can improve coordination among defendants, it also concentrates Axsome’s enforcement pressure. Generic launch remains blocked until the consolidated case resolves or the 30-month stay expires, whichever comes first.
Generic launch remains blockedSolriamfetol market exclusivity timeline now hinges on consolidated outcome
Sunosi® competes in the wakefulness-promoting agent market alongside modafinil and armodafinil generics. Successful generic entry by Aurobindo or Alkem would materially erode Axsome’s branded revenue. The consolidated litigation outcome will set the effective exclusivity horizon for solriamfetol, making the validity and enforceability of US12194016B2 a high-stakes commercial question for both branded and generic stakeholders.
Exclusivity timeline at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical patent holder — holder of US12194016B2 (Sunosi® solriamfetol)Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Generic pharmaceutical manufacturer and ANDA filer challenging Sunosi® listed patentsSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | WILLIAM HARE | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | McNeely, Hare & War LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order confirms that all four Axsome Sunosi® actions — spanning two defendants and filings from November 2024 through May 2025 — will proceed as a single matter. The joint request for consolidation, agreed to by all parties, suggests coordinated case management without any admission on the merits of infringement or validity. No claim construction, summary judgment, or trial findings have been issued. The operative question of whether Aurobindo and Alkem infringe Axsome’s Orange Book-listed patents covering solriamfetol remains entirely open.
US12194016B2 — Sunosi® solriamfetol wakefulness-promoting formulation
US12194016B2, filed under application number 18/627708, is listed in the FDA Orange Book for Axsome’s Sunosi® (solriamfetol) oral tablets — a dopamine and norepinephrine reuptake inhibitor approved for wakefulness promotion in adults with narcolepsy or obstructive sleep apnea. Orange Book listing confers significant legal protection: any ANDA referencing Sunosi® automatically triggers the right to file suit and invoke a 30-month regulatory stay, preventing FDA approval of the generic during that period absent a court ruling.
The strategic importance of US12194016B2 lies in its role as a barrier to generic solriamfetol entry. With Aurobindo and Alkem both having filed ANDAs, the patent’s validity and enforceability will determine the competitive dynamics of the wakefulness-promoting agent segment. For CNS-focused generic manufacturers, this patent represents a key freedom-to-operate hurdle. Branded competitors in the broader wake-promoting space should monitor the consolidated litigation for claim construction rulings that could affect analogous formulation or method patents.
Should you run an FTO analysis against US12194016B2?
Any generic manufacturer, contract development organisation, or branded competitor working with solriamfetol or structurally related dopamine/norepinephrine reuptake inhibitors should treat US12194016B2 as a live FTO risk. The patent’s Orange Book listing confirms it covers commercially marketed formulations of solriamfetol. Product teams developing oral tablet formulations in the CNS wakefulness or sleep disorder space should assess whether their compositions, dosing regimens, or manufacturing processes fall within the patent’s claim scope before advancing to ANDA or NDA filing.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US12194016B2, identify continuation applications stemming from 18/627708, and surface prior art that may bear on validity. For in-house IP teams tracking the consolidated D.N.J. litigation, Eureka’s docket monitoring tools can flag claim construction orders and trial dates that affect FTO exposure windows — enabling proactive risk management rather than reactive litigation response.
Run a freedom-to-operate analysis on US12194016B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases in CNS pharmaceuticals — D.N.J.
Explore related Orange Book patent infringement actions in the CNS and wakefulness-promoting drug space litigated in the District of New Jersey.
What this case signals for the CNS pharmaceutical IP landscape
The rapid four-filing, one-consolidation pattern in Axsome’s Sunosi® defence is a textbook ANDA enforcement playbook — and a signal to generic challengers.
Multiple ANDA filings trigger multiple suits — consolidation is the likely endpoint
Axsome’s filing of four separate actions across two defendants, then jointly seeking consolidation, reflects standard branded pharma enforcement strategy. Generic filers entering the same Orange Book-listed drug should anticipate parallel suits followed by a single merged proceeding, concentrating litigation risk and cost.
Orange Book listing of US12194016B2 signals Axsome’s intent to enforce broadly
Orange Book listing is a deliberate commercial and legal act. By listing US12194016B2 for Sunosi®, Axsome has signalled readiness to trigger automatic 30-month stays against any ANDA filer. Competitors and generic manufacturers should assess whether their formulations or methods fall within the scope of this patent before filing.
Axsome v Aurobindo — key questions answered
Case 2:25-cv-03721 was filed by Axsome Malta and Axsome Therapeutics on May 1, 2025 in the District of New Jersey, asserting infringement of US12194016B2 covering Sunosi® (solriamfetol). It was terminated on June 10, 2025 — 40 days later — when all parties jointly requested consolidation with three related Sunosi® ANDA actions against Aurobindo Pharma and Alkem Laboratories. No merits ruling was issued.
The patent at issue is US12194016B2, filed under application number 18/627708 and listed in the FDA Orange Book for Sunosi® (solriamfetol) oral tablets. Solriamfetol is a dopamine and norepinephrine reuptake inhibitor approved for wakefulness promotion in patients with narcolepsy or obstructive sleep apnea.
The case was closed after 40 days because all parties — Axsome, Aurobindo, and co-defendant Alkem Laboratories — jointly requested consolidation of all four related Sunosi® ANDA patent actions. Consolidation under Fed. R. Civ. P. 42(a) is standard practice when multiple cases share the same patents, product, and legal questions. The underlying infringement claims were not resolved and continue in the consolidated docket.
Orange Book listing of US12194016B2 means any ANDA filer referencing Sunosi® must provide a Paragraph IV certification challenging the patent if they seek to launch before patent expiry. Axsome may then sue within 45 days to trigger an automatic 30-month FDA approval stay. This mechanism gives Axsome substantial control over generic solriamfetol entry timing, making patent validity and enforceability central to Aurobindo’s and Alkem’s commercial timelines.
As of the consolidation order, four related actions were filed: No. 24-10617 (v. Alkem, filed Nov. 20, 2024), No. 24-10619 (v. Aurobindo, filed Nov. 20, 2024), No. 25-643 (v. Aurobindo, filed Jan. 21, 2025), and No. 25-3721 (v. Aurobindo, filed May 1, 2025). All four were consolidated into a single proceeding in the District of New Jersey, where the infringement and validity issues will be adjudicated.
PatSnap Eureka searches patents and litigation data to answer instantly.